MLMiguel Lança

Miguel Lança

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miguel Lança has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advancing genomic surveillance of respiratory syncytial virus in Portugal through an adapted amplicon-based whole-genome sequencing workflow

    by Miguel Lança, Vítor Borges, Vânia Gaio, Ana Paula Rodrigues, Daniela Santos, Sílvia Duarte, Camila Henriques, Licínia Gomes, Daniela Dias, Maria de Jesus Chasqueira, et al.

  • Open Access

    Nirsevimab Effectiveness Against RSV‐Related Hospitalisations in Children Under 24 Months: A Test‐Negative Case–Control Study in Portugal, 2024–2025

    by Vânia Gaio, Camila Henriques, Miguel Lança, Rita Marques, Raquel Marques, Marta Rodrigues, Sofia Almeida, Beatriz Sousa, Margarida Freitas, Diana Amaral, et al.

    We assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)‐related hospitalisation in eligible children (< 2 years) using a test‐negative case–control design within the VigiRSV network (weeks 43/2024 to 16/2025). Among 341 participants (median age: 2 months; 91.2% without known chronic condition), 137 (40.2%) tested RSV‐positive. Adjusted NE against RSV‐related hospitalisation was 78.5% (95%CI: 59.3–89.0). Sensitivity analyses confirmed the robustness of the results. These findings support Nirsevimab's effect in a predominantly healthy infant population and contribute to informing public health decisions for RSV immunisation.


  • Open Access

    Genetic and Epidemiological Insights Into Respiratory Syncytial Virus Infections: A Comparative Study of Hospitalized Versus Community Cases in Portugal (2021–2023)

    by Miguel Lança, Vânia Gaio, Ana Paula Rodrigues, Camila Henriques, Licínia Gomes, Daniela Dias, Maria de Jesus Chasqueira, Raquel Guiomar, Aryse Melo

    Background: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection (ARI) in young children, but its genetic diversity requires ongoing surveillance. Methods: From 2021 to 2023, a total of 619 and 94 RSV‐positive samples from the National Respiratory Syncytial Virus Surveillance Network (VigiRSV) and the Sentinel Influenza and other respiratory viruses surveillance network (Sentinel ISN), respectively, were analysed. The RSV A and RSV B typing was assessed by a multiplex real‐time RT‐PCR. Sanger sequencing was performed on a subset of samples ( n = 495). Phylogenetic analysis was carried out on partial glycoprotein G sequences. Clinical and epidemiological data were compared through Pearson Chi‐Square tests. Results: RSV Subgroup A was more prevalent (53.5%, 85/159) in the 2021/2022 season, whereas in the 2022/2023 season, it was RSV Subgroup B (82.1%, 435/530) in both networks. RSV A strains in VigiRSV clustered mainly to A.D .1 (39.0%, 39/100), whereas in Sentinel ISN, they clustered in A.D .5 (30.0%, 3/10). RSV Type B clustered mainly to B.D.E.1 (96.6%, 372/385) in both networks. All lineages cocirculated during the study period and in both surveillance networks. Regional clusters were identified for both subgroups. Conclusions: This study provides new insights into RSV genetic variability in Portugal, namely, the cocirculation of lineages and intravariability among lineages within both subgroups during the study period and in all Portuguese regions. However, our study is based on partial sequencing of the G gene, and because of this limitation, our results should be considered with great caution.


  • Open Access

    Renal carcinoma associated with end-stage kidney disease: A case series from a tertiary Portuguese hospital

    by João Ferreira Guerra, João Magalhães Pina, Vanessa Andrade, Miguel Brito Lança, Luís Campos Pinheiro

    End-stage kidney disease (ESKD) is associated with a higher incidence of renal cell carcinoma (RCC). Here we report a case series of 56 patients with ESKD who underwent radical nephrectomy for suspected renal masses at a tertiary hospital in Portugal from January 2017 to January 2024. Patient records were reviewed retrospectively to collect clinical, surgical, and pathological data. Among these patients, 12 had benign tumors, while 44 were diagnosed with malignant tumors, accounting for approximately 78.5% of the cohort. The histological analysis revealed the following distribution: clear cell RCC (20 cases, 45%), papillary RCC (11 cases, 25%), ACKD-associated RCC (6 cases, 14%), clear cell papillary RCC (4 cases, 9%), and chromophobe RCC (3 cases, 7%). Notably, the majority of patients (95.5%) had stage I malignant tumors, yet the prognosis for patients with ESKD was poorer compared to non-ESKD patients, with 7 patients succumbing during the follow-up period. This study underscores the complex relationship between ESKD and RCC, highlighting the challenges in diagnosis and management. Despite regular monitoring leading to early detection of tumors, the overall prognosis remains adversely affected by the compromised immune status and comorbid conditions prevalent in this population. The findings call for enhanced surveillance and personalized management strategies for RCC in patients with ESKD.

  • Open Access

    Unraveling Zinner Syndrome: Insights from a distinct case

    by João Ferreira Guerra, João Magalhães Pina, Vanessa Andrade, Miguel Brito Lança, Luís Campos Pinheiro

    Zinner Syndrome (ZS) is a rare congenital malformation characterized by a triad of unilateral renal agenesis, ipsilateral seminal vesicle cyst, and ejaculatory duct obstruction. Typically discovered incidentally in the second to fourth decades of life, it presents with varied symptoms, including lower urinary tract symptoms, painful ejaculation, hemospermia, perineal pain, and infertility in 45% of cases. This article describes the case of ZS, highlighting the diagnostic and management approaches. Diagnosis relies on imaging techniques: ultrasound for initial assessment, computed tomography (CT) for detailed anatomical information and magnetic resonance imaging (MRI) as the gold standard for its superior soft-tissue contrast. Treatment depends on symptom severity and cyst size, ranging from conservative management for asymptomatic patients to surgical intervention for symptomatic cases. The primary surgical treatment involves the removal of the seminal vesicle cysts, which can effectively relieve symptoms such as pain, urinary discomfort, and ejaculatory dysfunction, thereby significantly enhancing the patient's quality of life. Minimally invasive laparoscopic or robotic surgery is preferred for its reduced morbidity and shorter recovery time. Infertility management includes surgical relief of ejaculatory duct obstruction and assisted reproductive technologies when necessary. Regular follow-up is essential for monitoring recurrences. Future research should focus on long-term outcomes and standardized management protocols to improve patient quality of life.